Wells Fargo raised the firm’s price target on Procept BioRobotics to $47 from $44 and keeps an Overweight rating on the shares. The firm says it had a chance to speak to Procept’s management after the company pre-announced Q4 results. Its key takeaway is that 2024 consensus is appropriate, and the company is bullish on its capital funnel and handpiece outlook.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PRCT:
- PROCEPT BioRobotics® Announces Preliminary Fourth Quarter Revenue of $43.3 million to $43.6 million
- Procept BioRobotics price target raised to $50 from $48 at Truist
- PROCEPT BioRobotics to Present at the 35ᵗʰ Annual Piper Sandler Healthcare Conference in New York City
Questions or Comments about the article? Write to editor@tipranks.com